Advertisement

Reactions Weekly

, Volume 1734, Issue 1, pp 89–89 | Cite as

Blu-667/protein tyrosine kinase inhibitors

Acquired drug resistance and other toxicities: 44 case reports
Case report
  • 19 Downloads

Reference

  1. Piotrowska Z, et al. Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion. Cancer Discovery 8: 1529-1539, No. 12, Dec 2018. Available from: URL: http://doi.org/10.1158/2159-8290.CD-18-1022 - USACrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations